Screening in women's health, with emphasis on fetal Down's syndrome, breast cancer and osteoporosis

Human Reproduction Update

Volumn 12, Issue 5, 2006, Pages 499-512

  Wildschut, Hajo I J ^a   Peters, T J ^b   Weiner, Carl P ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Down's syndrome; Informed choice; Osteoporosis; Screening

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; CALCITONIN; CALCIUM; EXEMESTANE; IBANDRONIC ACID; LETROZOLE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; TAMOXIFEN; VITAMIN D;

BONE DENSITY; BREAST CANCER; BREAST SELF EXAMINATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DOWN SYNDROME; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY DIAGNOSIS; ECONOMIC ASPECT; FEMALE; FRAGILITY FRACTURE; GENETIC ANALYSIS; HEALTH CARE; HEALTH EDUCATION; HEALTH PRACTITIONER; HEALTH PROGRAM; HUMAN; LONGEVITY; MAMMOGRAPHY; MEDICAL INFORMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCREENING TEST; WOMEN'S HEALTH;

ADOLESCENT; ADULT; BREAST NEOPLASMS; DOWN SYNDROME; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS; PREGNANCY; PRENATAL DIAGNOSIS; SENSITIVITY AND SPECIFICITY; WOMEN'S HEALTH;

EID: 33747878832     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dml027     Document Type: Review

References (139)

1. [Anonymous] (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 83,1301-1308.
2. Advisory Committee on Breast Cancer Screening (2006) Screening for breast cancer in England: Past and future. NHS Cancer Screening Programmes, Sheffield (NHSBSP publication no. 61). Available from http://www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp61.pdf.
3. Alfirevic Z and Neilson JP (2004) Antenatal screening for Down's syndrome. BMJ 329,811-812.
4. Alfirevic Z, Sundberg K and Brigham S (2003) Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev 3,CD003252.
5. van Allen MI, Fung J and Jurenka SB (1999) Health care concerns and guidelines for adults with Down syndrome. Am J Med Genet 89,100-110.
6. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72,1117-1130.
7. Avenell A, Gillespie WJ, Gillespie LD and O'Connell DL (2005) Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 3,CD000227.
8. Avgidou K, Papageorghiou A, Bindra R, Spencer K and Nicolaides KH (2005) Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol 192,1761-1767.
9. Barratt A, Trevena L, Davey HM and McCaffery K (2004) Use of decision aids to support informed choices about screening. BMJ 329(7464),507-510.
10. Barton MB, Harris R and Fletcher SW (1999) The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: Should it be done? How? JAMA 282,1270-1280.
11. Baxter N and The Canadian Task Force on Preventive Health Care (2006) Preventive health care, 2001 update: Should women be routinely taught breast self-examination to screen for breast cancer? Canadian Task Force on Preventive Health Care. CMAJ 164,1837-1846.
12. Baxter NN, Virnig BA, Durham SB and Tuttle TM (2004) Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 96,443-448.
13. Bell R, Rankin J and Donaldson LJ; Northern Congenital Abnormality Survey Steering Group (2003) Down's syndrome: Occurrence and outcome in the north of England, 1985-99. Paediatr Perinat Epidemiol 17,33-39.
14. Benn PA, Borgida A, Horne D, Briganti S, Collins R and Rodis J (1997) Down syndrome and neural tube defect screening: The value of using gestational age by ultrasonography. Am J Obstet Gynecol 176,1056-1061.
15. Benn PA, Fang M and Egan JF (2005) Trends in the use of second trimester maternal serum screening from 1991 to 2003. Genet Med 7,328-331.
16. Beral V and Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362,419-427.
17. Bilardo CM, Müller MA, Pajkrt E, Clur SA and Bijlsma EK (2006) Normal ultrasound findings after increased nuchal translucency and normal karyotype: Can parents be reassured? Amsterdam, University of Amsterdam, Dissertation (ISBN-10: 90-9020443-1) 77-92.
18. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC et al. (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87,4528-4535.
19. Bonaiuti D, Shea B, Iovine R, Negrini S, Robinson V, Kemper HC, Wells G, Tugwell P and Cranney A (2002) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 3,CD000333.
20. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D and de Vet HC (2003) Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. BMJ 326,41-44.
21. Canick JA and MacRae AR (2005) Second trimester serum markers. Semin Perinatol 29,203-208.
22. Center JR, Nguyen TV, Schneider D, Sambrook PN and Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 353,878-882.
23. Cheffins T, Chan A, Haan EA, Ranieri E, Ryall RG, Keane RJ, Byron-Scott R, Scott H, Gjerde EM, Nguyen AM et al. (2000) The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia. BJOG 107,1453-1459.
24. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S et al.; Early Breast Cancer Trialists' Collaborative Group (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366,2087-2106.
25. Coast J (2004) Is economic evaluation in touch with society's health values? BMJ 329,1233-1236.
26. Collins JA, Blake JM and Crosignani PG (2005) Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11,545-560.
27. Consensus Development Conference (1991) Prophylaxis and treatment of osteoporosis. Osteoporos Int 1, 114-117.
28. Cooper C, Emkey RD, McDonald RH, Hawker G, Bianchi G, Wilson K and Schimmer RC (2003) Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88,4609-4615.
29. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, Wells G, Shea B and Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002a) Meta-analyses of therapies for postmenopausal osteoporosis.IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 23,524-528.
30. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, Wells G, Adachi J, Waldegger L and Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002b) Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 23,540-551.
31. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P et al.; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002c) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23,508-516.
32. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G and Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002d) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23,517-523.
33. Crossley JA, Aitken DA, Cameron AD, McBride E and Connor JM (2002) Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: A Scottish multicentre study. BJOG 109,667-676.
34. Cuckle HS (2006) Suboptimal Down syndrome screening test interpretation. Ultrasound Obstet Gynecol 27,6-8.
35. Cuckle HS, Wald NJ and Lindenbaum RH (1984) Maternal serum alphafetoprotein measurement: A screening test for Down syndrome. Lancet 1,926-929.
36. Cummings SR and Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359,1761-1767.
37. Cummings SR, Black DM and Rubin SM (1989) Lifetime risks of hip, Colles?, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149,2445-2448.
38. Darby SC, McGale P, Taylor CW and Peto R (2005) Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6,557-565.
39. Dixon JM (2006) Screening for breast cancer. BMJ 332,499-500.
40. Dormandy E, Michie S, Weinman J and Marteau TM (2002) Variation in uptake of serum screening: The role of service delivery. Prenat Diagn 22,67-69.
41. Dormandy E, Michie S, Hooper R and Marteau TM (2005) Low uptake of prenatal screening for Down syndrome in minority ethnic groups and socially deprived groups: A reflection of women's attitudes or a failure to facilitate informed choices? Int J Epidemiol 34,346-352.
42. Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, Myles JP and Warwick J (2005) Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res 7,258-265.
43. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, Hankins G, Berkowitz RL, Merkatz I, Craigo SD et al. (2004) First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: A population-based screening study (the FASTER Trial). Am J Obstet Gynecol 19,1446-1451.
44. Early Breast Cancer Trialists' Collaborative Group (2000) Ovarian ablation for early breast cancer. Cochrane Database Syst Rev 2,CD000485.
45. Early Breast Cancer Trialists' Collaborative Group (2001) Tamoxifen for early breast cancer. Cochrane Database Syst Rev 1,CD000486.
46. Early Breast Cancer Trialists' Collaborative Group (2002) Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 1,CD000487.
47. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365,1687-1717.
48. Edwards A, Unigwe S, Elwyn G and Hood K (2003) Effects of communicating individual risks in screening programmes: Cochrane systematic review. BMJ 327,703-709.
49. Eisen A, Rebbeck T, Wood W and Weber B (2000) Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 18,1980-1995.
50. Elmore JG, Armstrong K, Lehman CD and Fletcher SW (2005) Screening for breast cancer. JAMA 293,1245-1256.
51. Ensrud KE, Thompson DE, Cauley JA, Nevitt MC, Kado DM, Hochberg MC, Santora AC 2nd and Black DM (2000) Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 48,241-249.
52. Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC and Papapoulos SE (2005) Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 37,651-654.
53. Finkelstein JS (2006) Calcium plus vitamin D for postmenopausal women - bone appetit? N Engl J Med 354,750-752.
54. Fletcher SW and Elmore JG (2003) Clinical practice. Mammographic screening for breast cancer. N Engl J Med 348,1672-1680.
55. Fracheboud J and de Koning HJ (2006) Screening for breast cancer. In Wildschut HIJ, Weiner CP and Peters TJ (eds) When to Screen in Obstetrics and Gynecolgogy, 2nd edn. Saunders Elsevier Ltd, Philadelphia, pp. 591-602.
56. Fracheboud J, Otto SJ, van Dijck JA, Broeders MJ, Verbeek AL and de Koning HJ; National Evaluation Team for Breast cancer screening (NETB) (2004) Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br J Cancer 91,861-867.
57. Freedman DA, Petitti DB and Robins JM (2004) On the efficacy of screening for breast cancer. Int J Epidemiol 33,43-55.
58. Freeman SB, Taft LF, Dooley KJ, Allran K, Sherman SL, Hassold TJ, Khoury MJ and Saker DM (1998) Population-based study of congenital heart defects in Down syndrome. Am J Med Genet 80,213-217.
59. Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB and DeLuca HF (1979) Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients. J Clin Invest 64,729-736.
60. Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R and Thun M (2003) Trends in breast cancer by race and ethnicity. CA Cancer J Clin 53,342-355.
61. Gilbert RE, Augood C, Gupta R, Ades AE, Logan S, Sculpher M and van der Meulen JH (2001) Screening for Down's syndrome: Effects, safety, and cost effectiveness of first and second trimester strategies. BMJ 323,423-425.
62. Gøtzsche PC (2004) On the benefits and harms of screening for breast cancer. Int J Epidemiol 33,56-64.
63. Green JM, Hewison J, Bekker HL, Bryant LD and Cuckle HS (2004) Psychosocial aspects of genetic screening of pregnant women and newborns: A systematic review. Health Technol Assess 8,iii, ix-x, 1-109.
64. Greiser CM, Greiser EM and Doren M (2005) Menopausal hormone therapy and risk of breast cancer: A meta-analysis of epidemiological studies and randomized controlled trials. Hum Reprod Update 11,561-573.
65. Grijseels EW, Laudy JA, Galjaard RJ and Wildschut HI (2004) Prenatal investigations for Down's syndrome: Medical-technical considerations and dilemmas arising from current screening methods [Article in Dutch]. Ned Tijdschr Geneeskd 148,2166-2171.
66. Haak MC and van Vugt JM (2003) Pathophysiology of increased nuchal translucency: A review of the literature. Hum Reprod Update 9,175-184.
67. Heckerling PS and Verp MS (1991) Amniocentesis or chorionic villus sampling for prenatal genetic testing: A decision analysis. J Clin Epidemiol 44,657-670.
68. Humphrey LL, Helfand M, Chan BK and Woolf SH (2002) Breast cancer screening: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137,347-360.
69. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SA, Black HR, Blanchette P et al.; Women's Health Initiative Investigators (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354,669-683.
70. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55,10-30.
71. Johnson SR (2006) Osteoporsis. In Wildschut HIJ, Weiner CP and Peters TJ (eds) When to Screen in Obstetrics and Gynecolgogy, 2nd edn. Saunders Elsevier Ltd, Philadelphia, pp. 673-681.
72. Julian-Reynier C, Aurran Y, Dumaret A, Maron A, Chabal F, Giraud F and Ayme S (1995) Attitudes towards Down's syndrome: Follow up of a cohort of 280 cases. J Med Genet 32,597-599.
73. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, Avril A, Sylvester R, Mignolet F, Bartelink H et al. (2000) Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 355, 528-533.
74. Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Eisman JA, McCloskey EV, Mellstrom D, Melton LJ 3rd, Pols HA et al. (2004) A family history of fracture and fracture risk: A meta-analysis. Bone 35,1029-1037.
75. Kanis JA, Johnell O, Oden A, Johansson H, de Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D et al. (2005) Smoking and fracture risk: A meta-analysis. Osteoporos Int 16,155-162.
76. Khoshnood B, De Vigan C, Vodovar V, Goujard J and Goffinet F (2004) A population-based evaluation of the impact of antenatal screening for Down's syndrome in France, 1981-2000. BJOG 111,485-490.
77. de Koning HJ (2003) Mammographic screening: Evidence from randomised controlled trials. Ann Oncol 14,1185-1189.
78. Krantz D, Goetzl L, Simpson JL, Thom E, Zachary J, Hallahan TW, Silver R, Pergament E, Platt LD, Filkins K et al.; First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group (2004) Association of extreme first-trimester free human chorionic gonadotrophin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 191,1452-1458.
79. de Laet CE, van der Klift M, Hofman A and Pols HA (2002) Osteoporosis in men and women: A story about bone mineral density thresholds and hip fracture risk. J Bone Miner Res 17,2231-2236.
80. Leonard GD and Swain SM (2004) Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96,906-920.
81. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD et al.; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium (2005) First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 353,2001-2011.
82. Marteau TM (1995) Towards informed decisions about prenatal testing: A review. Prenat Diagn 15,1215-1226.
83. Marteau TM and Dormandy E (2001) Facilitating informed choice in prenatal testing: How well are we doing? Am J Med Genet 106,185-190.
84. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA and Kiel DP (2004) Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350,2042-2049.
85. Meijers-Heyboer H (2006) Genetic predisposition to gynaecologic cancers. In Wildschut HIJ, Weiner CP and Peters TJ (eds) When to Screen in Obstetrics and Gynecolgogy, 2nd edn. Saunders Elsevier Ltd, Philadelphia, pp.574-590.
86. Melton LJ 3rd (2000) Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res 15,2309-2314.
87. Melton LJ 3rd (2003) Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 18,1139-1141.
88. Melton LJ 3rd, Johnell O, Lau E, Mautalen CA and Seeman E (2004) Osteoporosis and the global competition for health care resources. J Bone Miner Res 19,1055-1058.
89. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP et al. (2004) Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350,2033-2041.
90. Minelli C, Abrams KR, Sutton AJ and Cooper NJ (2004) Benefits and harms associated with hormone replacement therapy: Clinical decision analysis. BMJ 328,371-377.
91. Morris JK, Wald NJ and Watt HC (1999) Fetal loss in Down syndrome pregnancies. Prenat Diagn 19,142-145.
92. Morris JK, Mutton DE and Alberman E (2002) Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 9,2-6.
93. Moss S, Waller M, Anderson TJ, Cuckle H and Trial Management Group (2005) Randomised controlled trial of mammographic screening in women from age 40: Predicted mortality based on surrogate outcome measures. Br J Cancer 92,955-960.
94. Müller MA, Bleker OP, Bonsel GJ, Knegt AC and Bilardo CM (2006) First trimester screening of Down syndrome in an unselected Dutch population: uptake, performance and impact on invasive testing. Ultrasound Obstet Gynecol, in press.
95. Mulvey S and Wallace EM (2000) Women's knowledge of and attitudes to first and second trimester screening for Down's syndrome. BJOG 107,1302-1305.
96. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344,1434-1441.
97. Nelson HD, Humphrey LL, Nygren P, Teutsch SM and Allan JD (2002) Postmenopausal hormone replacement therapy: Scientific review. JAMA 288,872-881.
98. Nelson HD, Huffman LH, Fu R, Harris EL and U.S. Preventive Services Task Force (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 143,362-379.
99. Nicolaides KH (2004) Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 191,45-67.
100. Nicolaides KH, Spencer K, Avgidou K, Faiola S and Falcon O (2005) Multicenter study of first-trimester screening for trisomy 21 in 75,821 pregnancies: Results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25,221-226.
101. Olsen O and Gøtzsche PC (2001) Screening for breast cancer with mammography. Cochrane Database Syst Rev 4,CD001877.
102. Perni SC, Predanic M, Kalish RB, Chervenak FA and Chasen ST (2006) Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials. Am J Obstet Gynecol 194,127-130.
103. Peters TJ, Wildschut HIJ and Weiner CP (2006) Epidemiologic considerations in screening. In Wildschut HIJ, Weiner CP and Peters TJ (eds) When to Screen in Obstetrics and Gynecology, 2nd edn. Saunders Elsevier Ltd, Philadelphia, pp. 1-14.
104. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J and Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91,943-949.
105. Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson NK and Harris MM (1991) Prevention of postmenopausal osteoporosis: A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 325,1189-1195.
106. Raisz LG (2004) Homocysteine and osteoporotic fractures - culprit or bystander? N Engl J Med 350,2089-2090.
107. Reynolds TM (2003) Down's syndrome screening is unethical: Views of today's research ethics committees. J Clin Pathol 56,268-270.
108. Rimer BK, Briss PA, Zeller PK, Chan EC and Woolf SH (2004) Informed decision making: What is its role in cancer screening? Cancer 101,1214-1228.
109. Roizen NJ and Patterson D (2003) Down's syndrome. Lancet 361,1281-1289.
110. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al.; Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288,321-333.
111. Rowe RE, Garcia J and Davidson LL (2004) Social and ethnic inequalities in the offer and uptake of prenatal screening and diagnosis in the UK: A systematic review. Public Health 118,177-189.
112. Saenz RB (1999) Primary care of infants and young children with Down syndrome. Am Fam Physician 59,381-390,392,395-396.
113. Santalahti P, Hemminki E, Latikka AM and Ryynanen M (1998) Women's decision-making in prenatal screening. Soc Sci Med 4,1067-1076.
114. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JP and Pols HA (2004) Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study. Bone 34,195-202.
115. Siffel C, Correa A, Cragan J and Alverson CJ (2004) Prenatal diagnosis, pregnancy terminations and prevalence of Down syndrome in Atlanta. Birth Defects Res A Clin Mol Teratol 70,565-571.
116. Simpson JL (2005) Choosing the best prenatal screening protocol. N Engl J Med 353,2068-2070.
117. Smith I and Chua S (2006) Medical treatment of early breast cancer. I: adjuvant treatment. BMJ 332,34-37.
118. Smith-Bindman R, Hosmer W, Feldstein VA, Deeks JJ and Goldberg JD (2001) Second-trimester ultrasound to detect fetuses with Down syndrome: A meta-analysis. JAMA 285,1044-1055.
119. Smith-Bindman R, Chu PW, Miglioretti DL, Sickles EA, Blanks R, Ballard-Barbash R, Bobo JK, Lee NC, Wallis MG, Patnick J et al. (2003) Comparison of screening mammography in the United States and the United Kingdom. JAMA 290,2129-2137.
120. Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD and Nicolaides KH (2005) Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 192,1005-1021.
121. Spencer K (2001) What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence whether first trimester detection rates are superior to those in the second trimester? Prenat Diagn 21,788-789.
122. Spencer K (2006) First trimester screening for aneuploidy. In Wildschut HIJ, Weiner CP and Peters TJ (eds) When to Screen in Obstetrics and Gynecology, 2nd edn. Saunders Elsevier Ltd, Philadelphia, pp. 201-216.
123. Stein Z, Stein W and Susser M (1986) Attrition of trisomies as a maternal screening device: An explanation of the association of trisomy 21 with maternal age. Lancet 1,944-947.
124. Tabár L, Duffy SW, Yen MF, Warwick J, Vitak B, Chen HH and Smith RA (2002) All-cause mortality among breast cancer patients in a screening trial: Support for breast cancer mortality as an end point. J Med Screen 9,159-162.
125. Thornton H, Edwards A and Baum M (2003) Women need better information about routine mammography. BMJ 327,101-103.
126. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M et al.; Breast International Group (BIG) 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353,2747-2757.
127. Van den Berg M, Timmermans DR, Kleinveld JH, Garcia E, van Vugt JM and van der Wal G (2005a) Accepting or declining the offer of prenatal screening for congenital defects: Test uptake and women's reasons. Prenat Diagn 25,84-90.
128. Van den Berg M, Timmermans DR, Ten Kate LP, van Vugt JM and van der Wal G (2005b) Are pregnant women making informed choices about prenatal screening? Genet Med 7,332-338.
129. Van der Klift M, De Laet CE, McCloskey EV, Hofman A and Pols HA (2002) The incidence of vertebral fractures in men and women: The Rotterdam Study. J Bone Miner Res 17,1051-1056.
130. Wald NJ, Kennard A, Hackshaw A and McGuire A (1997) Antenatal screening for Down's syndrome. J Med Screen 4,181-246.
131. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L and Mackinson AM; SURUSS Research Group (2003) First and second trimester antenatal screening for Down's syndrome: The results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 7,1-77.
132. Wald NJ, Rodeck C, Hackshaw AK and Rudnicka A (2004) SURUSS in perspective. BJOG 111,521-531.
133. Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez; C, Ghafoor A and Thun M (2004) Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 54,78-93.
134. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D and Cranney A; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23,529-539.
135. Wessels MW, Los FJ, Frohn-Mulder IM, Niermeijer MF, Willems PJ and Wladimiroff JW (2003) Poor outcome in Down syndrome fetuses with cardiac anomalies or growth retardation. Am J Med Genet 116, 147-151.
136. Westenberg AH, Rutgers EJ, Peterse JL, Hendriks JR, Beex LV and van Tienhoven G (2003) The treatment of ductal carcinoma in situ (DCIS) of the breast [Article in Dutch]. Ned Tijdschr Geneeskd 147,2157-2161.
137. Wilson JM and Jungner YG (1968) Principles and practices for screening of disease. World Health Organization, Geneva. Public Health Papers no. 34.
138. Yang Q, Rasmussen SA and Friedman JM (2002) Mortality associated with Down's syndrome in the USA from 1983 to 1997: A population-based study. Lancet 359,1019-1025.
139. Yen MF, Tabár L, Vitak B, Smith RA, Chen HH and Duffy SW (2003) Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 39,1746-1754.